Pharma Stability: Insights, Guidelines, and Expertise
In early pharmaceutical R&D, speed is critical. With multiple formulations under evaluation, developers must quickly identify those most likely to succeed. Accelerated stability testing provides a fast, cost-effective way to assess the relative stability of various prototypes under controlled stress conditions, allowing prioritization of robust candidates.
Click to read the full article.
Stability monitoring frequency defines how often samples are analyzed throughout the study. Key objectives include:
Click to read the full article.
Biologic formulations, especially those in liquid or reconstituted form, require sterile barriers to maintain their potency and safety. A breach in the container closure system can result in:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
While excipients are considered “inactive” ingredients, they can interact physically or chemically with the active pharmaceutical ingredient (API) under stress conditions such as heat, humidity, and light. These interactions can accelerate degradation or alter bioavailability, posing serious risks to product quality and patient safety.
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.
Intermediate condition testing is essential when accelerated stability results show significant change or when biologics and other temperature-sensitive products are evaluated. Managing this data manually introduces risks such as:
Click to read the full article.
Pharmaceutical products marketed in countries with pronounced seasonal fluctuations often experience temperature and humidity conditions far beyond standard ICH testing parameters. If not anticipated, this variability can lead to:
Click to read the full article.
Available from Pharma SOP:
Click to read the full article.